StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH – Free Report) in a report published on Wednesday. The firm issued a sell rating on the stock. Separately, Roth Mkm reissued a buy rating and set a $40.00 price objective on shares of Bio-Path in a research report on Thursday, April 18th. Get Our Latest Research […]